A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Norwegian National Air Ambulance Services Choose Danish Blood/IV Fluid Warmer, ̊M Warmer System ( ̊MEQU)

Norwegian National Air Ambulance Services

 

˚MEQU, an innovative MedTech company from Denmark, is pleased to announce that it has won a public tender to provide portable blood and IV-fluid warming devices (˚M Warmer System) to Norwegian National Air Ambulance Services (Luftambulansetjenesten HF). 

Norwegian National Air Ambulance Services is responsible for all air ambulances (both fixed-wing and helicopters) and acute cars located at 13 bases throughout the country and is one of the most innovative and advanced HEMS (helicopter emergency medical services) programs in the world. The ˚M Warmer System was the only device meeting all mandatory requirements and was chosen due to its high quality – small size and light weight, heating capacity, and not least user-friendliness.

Prehospital fluid resuscitation is known to increase the survival rate of trauma patients. For this reason, carrying blood products onboard aircraft has been initiated by major European HEMS in recent years despite its complex and costly process in terms of blood supply and staff training. Moreover, aircraft should be equipped with a blood/IV fluid warmer as all fluids should be warmed up to body temperature before the infusion to avoid unnecessary cooling of the patient.

Ulrik Krogh Andersen (CEO) commented,“prehospital fluid resuscitation before arriving at a hospital is shown to significantly reduce mortality among severely injured patientsWe are thankful that Norwegian National Air Ambulance Services chose our ˚M Warmer System to treat their patients, so we accelerate our mission to improve the survival and recovery rate of patients in critical situations.”

Peter Skade (GLOBAL SALES DIRECTOR) commented, “winning this tender is a confirmation that ˚M Warmer System is a superior solution as it is easy to set up and use and has efficient and powerful warming capacity. The ˚M Warmer System is now adopted by leading HEMS throughout the Nordic countries, UK, mainland Europe and Australia.”

The ˚M Warmer System was awarded the Red Dot Design Award in 2018 for its minimalist expression, user-friendliness, and intuitive design that together reduce the risk of human errors and delays. ˚M Warmer is currently used both in pre-hospital and in-hospital settings, and ˚MEQU is continuously developing its technology to bring warm blood and IV fluids to more patients.

SourceMEQU
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy